After signing up, you'll start to receive regular news updates from us.
GeneGo and Elsevier Announce Collaboration
Complete the form below to unlock access to ALL audio articles.
GeneGo, Inc. and Elsevier MDL has announced the collaboration. The latest version of GeneGo’s data mining platform MetaCore 4.0 will be integrated with the MDL® suite of databases via the DiscoveryGate® content platform.
Researchers will be able to identify drug targets and bioactive compounds via pathway analysis and retrieve comprehensive information on their synthesis, biological effects, commercial availability and relevant literature within one application.
"The integration of MDL databases with GeneGo's pathways information systems enables scientists to bridge the gap between cell biology and organic chemistry," comments Steve Young, Director of MDL Content Strategy.
"For the first time, biologists will be able to quickly review cheminformatics data of small molecules involved in biological pathways and chemists will be able to view molecular pathway information related to their lead compounds."
"Lately, a number of customers approached us with requests for functional analysis of the effects of drug-like compounds rather than genomic data," says Julie Bryant, VP Business development at GeneGo.
"Although pathways and network analysis of bioactive compounds is a common practice in MetaCore, we partnered with Elsevier MDL for in depth coverage of literature and patentderived information relevant for compounds."
"We are very pleased to be working with Elsevier MDL, the market leader in medicinal chemistry knowledge databases, Integration with the Elsevier MDL chemistry space opens up new applications for our products in medicinal chemistry, including high-throughput and high-content screening, hit selection and validation, lead development programs and chemogenomics."
